Feb 14, 2013, 02.09 PM | Source: Reuters
Shares in Dr Reddy's Laboratories fall 2.1 percent on worries the drug maker will post lower-than-expected October-December earnings, due later in the day
Margins are also expected to see significant erosion, several dealers add.
Dr Reddy's could miss consensus earnings per share (EPS) estimates by 6 percent in the October-December quarter, according to Thomson Reuters StarMine SmartEstimate data, which measures the forecasts from top-ranked analysts against wider forecasts. * StarMine SmartEstimate suggests EPS for the quarter ending December at Rs 26.03 compared with mean estimate of Rs 27.89.
Net Sales are expected to increase by 4.6 percent
Net Sales are expected to increase by 0.4 percent
US Food and Drug Administration (USFDA) will re-au
Nomura has a buy ratings on Dr Reddy’s, Glenmark